16 September 2026 editorial review · Item
NewcelX NCEL-101 / IsletRx: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: NewcelX/IsletRx primary corporate materials describe pre-IND consultation. A meeting is not IND clearance, and does not demonstrate human efficacy or establish an approval date.
- Programme/sponsor/conference source boundary: NewcelX pipeline: IsletRx / NCEL-101 for type 1 diabetes (manufacturer); NewcelX submits pre-IND package to FDA for NCEL-101 for type 1 diabetes (manufacturer); NewcelX announces strategic collaboration with Eledon to advance NCEL-101 program for type 1 diabetes (manufacturer); NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes (manufacturer).